Stockreport

EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program [Yahoo! Finance]

Cybin Inc. Common Shares  (CYBN) 
PDF The company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for Central Nervous System (CNS) disorders. In addition, the compan [Read more]